Biocad for the first time in the Russian pharmaceutical industry published a report on corporate social responsibility (CSR) on the basis of the international GRID Standards (Global Reporting Initiative), the company reports.
According to IQVIA, Biocad entered the top 15 largest companies in the Russian pharmaceutical market.
“More than 4 billion rubles invested by the company in scientific developments and more than 45 million rubles. – in educational projects. About 30 thousand people became participants in prevention and patient support programs. A comprehensive system of environmental management has been developed, direct greenhouse gas emissions are systematically reduced. It is planned that by 2030 the emissions of industrial complexes of the company will be reduced by 30%. The development strategy was approved until 2023”, the report says.
“As part of the CSR strategy, we invest in scientific and innovative activities, increase access to highly effective treatment, develop regions of presence, take care of the health of employees and their families, implement programs for the prevention of socially significant diseases and introduce an integrated approach to environmental impact management”, said Irina Kenyukhova, Biocad External Communications Director.
The report was prepared during the pandemic and some studies had to be postponed in order to deal with current tasks – the development of a vaccine and trials of levilimab, a drug for the treatment of a complicated course of COVID-19.
